Substance / Medication

Sorafenib tosylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J, Hoyle M, Green C et al. · Health Technol Assess · 2010
PMID: 20028613Meta-Analysis
In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth M J, Sandmann S, Engel K et al. · Drug Metab Dispos · 2010
PMID: 20413726Observational
Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.
Shin Dongheon, Kim Chaerin, Chae Yeon et al. · J Am Anim Hosp Assoc · 2024
PMID: 39480738Case Report
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Joshita Satoru, Yoshizawa Kaname, Sano Kenji et al. · Intern Med · 2010
PMID: 20519814Case Report
Sorafenib tosylate-loaded nanosuspension: preparation, optimization, andcytotoxicity study against human HepG2 carcinoma cells.
Khanuja Harpreet Kaur, Awasthi Rajendra, Dureja Harish · J Chemother · 2024
PMID: 37881008Other
Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Yadav Khushwant S, Raut Hrushikesh C, Nijhawan Harsh P · Pharm Dev Technol · 2023
PMID: 37665569Other
Natural Polymer-Based Nanogel for pH-Responsive Delivery of Sorafenib Tosylate in Hemangiosarcoma.
Mali Kiran K, Gavhane Yogeshkumar N, Chakole Rita D · AAPS PharmSciTech · 2024
PMID: 38605211Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sorafenib tosylate (substance)
SNOMED CT
432886002
UMLS CUI
C1676709

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.